30-Apr-2026
Alpha Tau to Present Pooled Pancreatic Cancer Alpha DaRT Data at 2026 ASCO Meeting
TipRanks (Mon, 27-Apr 9:40 AM ET)
Globe Newswire (Mon, 27-Apr 9:01 AM ET)
Globe Newswire (Thu, 23-Apr 9:02 AM ET)
Globe Newswire (Thu, 23-Apr 9:01 AM ET)
Globe Newswire (Tue, 31-Mar 9:15 AM ET)
Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
Globe Newswire (Mon, 16-Mar 10:02 AM ET)
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
Globe Newswire (Mon, 9-Mar 4:02 PM ET)
Globe Newswire (Tue, 24-Feb 9:00 AM ET)
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
Alpha Tau Medical Ltd. - trades on the NASDAQ stock market under the symbol DRTS.
As of April 30, 2026, DRTS stock price climbed to $8.34 with 738,084 million shares trading.
DRTS has a beta of 0.96, meaning it tends to be less sensitive to market movements. DRTS has a correlation of 0.05 to the broad based SPY ETF.
DRTS has a market cap of $707.40 million. This is considered a Small Cap stock.
In the last 3 years, DRTS traded as high as $8.60 and as low as $1.75.
The top ETF exchange traded funds that DRTS belongs to (by Net Assets): IZRL, EHLS.
DRTS has outperformed the market in the last year with a price return of +207.7% while the SPY ETF gained +31.0%. DRTS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +15.2% and +5.8%, respectively, while the SPY returned +3.8% and +2.7%, respectively.
DRTS support price is $7.08 and resistance is $7.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DRTS shares will trade within this expected range on the day.
